ClinConnect ClinConnect Logo
Search / Trial NCT06511999

Continuous Jugular Venous Oxygen Saturation (SjO2) Measurement After Cardiac Arrest

Launched by BYRON DRUMHELLER · Jul 15, 2024

Trial Information

Current as of July 23, 2025

Not yet recruiting

Keywords

Jugular Venous Oxygen Saturation Neuromonitoring

ClinConnect Summary

This clinical trial is studying a new method to measure the oxygen levels in the blood leaving the brain of patients who have been successfully resuscitated after a cardiac arrest but remain in a coma. After a cardiac arrest, the brain can be at risk for further injury, and understanding how well it is receiving oxygen is crucial for treatment. The researchers want to see if a special catheter, which can continuously measure this oxygen level without needing to take blood samples frequently, is accurate compared to the standard method that requires sending blood to a lab for testing.

To participate in this study, individuals must be at least 18 years old and have been resuscitated from cardiac arrest, remaining comatose (not responding) for at least 30 minutes. However, those with certain conditions, like traumatic brain injuries or severe instability, will not be eligible. If someone joins the trial, they can expect to have the new catheter placed to monitor their brain's oxygen levels, while their health will be closely observed by a specialized medical team. This research aims to provide quicker and more accurate information about brain health in patients recovering from cardiac arrest.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • • Adults (\>=18 years old) resuscitated from out-of-hospital or in-hospital cardiac arrest who remain comatose (motor Glasgow coma scale \<=4) for at least 30 minutes when examined off sedation/neuromuscular blockade.
  • Exclusion Criteria:
  • Cardiac arrest due to traumatic brain injury, intracranial bleeding, or ischemic stroke
  • Cervical spine fracture
  • Need for immediate prone positioning for severe hypoxemic respiratory failure
  • Marked hemodynamic instability precluding priority of any neuromonitoring (multiple recurrent cardiac arrests, norepinephrine equivalents \> 1.5 mcg/kg/min)
  • Moribund neurological status based upon initial clinical, radiographic and historical assessment (e.g. diffuse cerebral edema or herniation on head computed tomography)
  • Pregnancy
  • Prisoners

About Byron Drumheller

Byron Drumheller is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative therapeutic solutions. With a focus on integrity and scientific rigor, Byron Drumheller oversees a diverse portfolio of clinical studies across various therapeutic areas. The organization collaborates with leading researchers and healthcare professionals to ensure the highest standards of quality and compliance, fostering a culture of transparency and collaboration. Through its strategic partnerships and commitment to patient-centered research, Byron Drumheller aims to drive the development of groundbreaking treatments that address unmet medical needs.

Locations

Pittsburgh, Pennsylvania, United States

Patients applied

0 patients applied

Trial Officials

Byron Drumheller, MD

Principal Investigator

University of Pittsburgh

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported